Meanwhile, at CureVac
The German biotech company that woke up Sunday in the middle of an international incident insists there’s nothing to see here.
CureVac executives spent an hour on the phone with reporters yesterday to dispel reports that President Trump tried to secure an exclusive right to the company’s in-development vaccine for the novel coronavirus. That story “has been hitting us like a bus,” CureVac CEO Franz-Werner Haas said, but it “is just not right.”
If you missed the saga, it began on March 2, when CureVac’s ex-CEO, Dan Menichella, attended a meeting at the White House to explain the company’s messenger RNA technology to Trump. Nine days later, Menichella was replaced by CureVac founder Ingmar Hoerr. Then came the reports that Trump made some sort of mystery overture, and then Hoerr, five days into his new job, stepped down for medical reasons. Things got stranger on Monday when billionaire Dietmar Hopp, whose investment fund is CureVac’s largest shareholder, told reporters that there was some sort of offer from the U.S. but that it was vetoed.
But “what Dietmar Hopp meant to say is he was summarizing all the information he had heard,” said Friedrich von Bohlen, a CureVac board member partner at Hopp’s fund. He was “not saying ‘I know something no one else knows,’” von Bohlen said. So there’s that.
CureVac executives spent an hour on the phone with reporters yesterday to dispel reports that President Trump tried to secure an exclusive right to the company’s in-development vaccine for the novel coronavirus. That story “has been hitting us like a bus,” CureVac CEO Franz-Werner Haas said, but it “is just not right.”
If you missed the saga, it began on March 2, when CureVac’s ex-CEO, Dan Menichella, attended a meeting at the White House to explain the company’s messenger RNA technology to Trump. Nine days later, Menichella was replaced by CureVac founder Ingmar Hoerr. Then came the reports that Trump made some sort of mystery overture, and then Hoerr, five days into his new job, stepped down for medical reasons. Things got stranger on Monday when billionaire Dietmar Hopp, whose investment fund is CureVac’s largest shareholder, told reporters that there was some sort of offer from the U.S. but that it was vetoed.
But “what Dietmar Hopp meant to say is he was summarizing all the information he had heard,” said Friedrich von Bohlen, a CureVac board member partner at Hopp’s fund. He was “not saying ‘I know something no one else knows,’” von Bohlen said. So there’s that.
.png)
No hay comentarios:
Publicar un comentario